Blanket Purchase Agreement V797D70074-75N90020A00004
Award Date
4/27/20
Last Date to Order
4/26/25
Federal Agency
NIH Clinical Center
Awardee
Seqirus USA Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The National Institutes of Health Clinical Center awarded Sanofi Pasteur Inc. a blanket purchase agreement to deliver influenza vaccines in support of the agency's medical programs. Under the agreement and subsequent calls issued against the Pharmaceuticals and Drugs schedule, Sanofi Pasteur will supply its influenza virus vaccine through April 2025 from manufacturing locations in Swiftwater, Pennsylvania and Bethesda, Maryland. Vaccines will be provided on a firm-fixed-price basis under task...
Seqirus USA Inc., a global biotechnology company, has been awarded a multiple-award Federal Supply Schedule (FSS) contract V797D70074 by the U.S. Department of Veterans Affairs (VA) to provide a range of influenza vaccines and pharmaceuticals. The contract, which is set under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, enables Seqirus to deliver a variety of influenza vaccine formulations and presentations, including multi-dose vials, pre-filled syringes, and specialized vaccines for...
The Federal Supply Schedule contract awarded to Seqirus USA Inc. by the Veterans Integrated Service Network 12 (VISN 12) is for the supply of drugs, pharmaceuticals, and hematology-related products. As a foreign-owned, for-profit manufacturer of goods, Seqirus USA Inc. has been a registered federal contractor since 2008 and specializes in the development, manufacturing, and delivery of influenza vaccines to various federal government agencies. The contract has a ceiling value of $2,555,130.00...
The Centers for Disease Control and Prevention awarded Seqirus USA Inc. a multiple award indefinite delivery contract with a potential value of $129.8 million to supply pediatric influenza vaccines through February 2028. Task orders will be issued against the contract to procure required vaccines annually to support the CDC's national immunization programs. As a leading manufacturer of influenza vaccines, Seqirus will deliver various formulations of pediatric flu vaccines to the CDC for...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development and delivery. The $143 million IDC is for the supply of adult influenza vaccines, and a separate $208 million IDC is for pediatric influenza vaccines, to support the CDC's nationwide immunization programs from 2022-2023. Seqirus USA Inc. has also been awarded several other high-value...
The Department of Veterans Affairs National Acquisition Center awarded an indefinite delivery contract to Seqirus USA Inc. to deliver influenza virus vaccines for the 2022-2023 season to the VA, Federal Bureau of Prisons, Indian Health Service, and James A. Lovell Federal Health Care Center. Task orders under the contract, with a potential value of $69,190,924.13, provide vaccines including 10-dose vials, single dose syringes in boxes of 10, and an adjuvant vaccine for individuals aged 65 and...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian agency within the Department of Health and Human Services, to Seqirus USA Inc. The contract has a ceiling value of $27,015,000 and is for the delivery of adult influenza vaccines for the 2019-2020 flu season. Seqirus USA Inc., through its Seqirus USA, Inc. division, is a global biotechnology company specializing in the development, manufacturing, and delivery of influenza...
This federal contract IDV award, SPE2DP25D0004, is a single-award Indefinite Delivery Contract valued at $6,857,675.50 and administered by the Defense Logistics Agency (DLA) Troop Support. The contract was awarded to Seqirus USA Inc., a foreign-owned, for-profit manufacturer of influenza vaccines. The contract aims to procure injectable, egg-free influenza vaccines for the 2025-2026 flu season, with an estimated annual quantity of 280,000 doses and a maximum of 150% of the annual estimate. The...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency's Medical Supply Chain unit to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development and delivery. The contract, valued at $36,120,112.50, aims to procure approximately 3.23 million doses of injectable influenza virus vaccines in multi-dose vials and pre-filled syringes for various age groups, including elderly, adult, and pediatric populations. The vaccines are intended...
This indefinite delivery contract (IDC) was awarded by the Defense Logistics Agency Troop Support Medical to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $27.5M IDC, which has a period of performance through June 2019, aims to procure approximately 3.6 million doses of injectable influenza vaccine in multi-dose vials and pre-filled syringes for various ages, including pediatric formulations. The contract supports...